Glutathione inhalation - Renovion

Drug Profile

Glutathione inhalation - Renovion

Alternative Names: Arina-1; Inhaled L-glutathione - Renovion

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Renovion
  • Class Antineoplastics; Chemoprotectants; Oligopeptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lung disorders
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Asthma; Cystic fibrosis; Lung disorders

Most Recent Events

  • 24 Jul 2017 Duke University plans a phase I trial for Lung disorders (lung dysfunction following lung transplant) in USA (NCT03226431)
  • 06 Jan 2017 Glutathione inhalation - Renovion receives Orphan Drug status for Lung disorders (lung dysfunction following lung transplant) in USA
  • 01 Feb 2016 Renovion receives patent allowance for glutathione inhalation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top